FT. MYERS, Fla., March 12 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. announced today that it was still in the process of finalizing its 2007 audited financial statements with its auditors, and as a result, does not expect to release its fourth quarter and full year 2007 financial results until Tuesday, March 18. However, the company is releasing its key revenue and operating metrics now, which are not expected to change. The table below includes revenue and key operating metrics for the three and twelve month periods ended December 31, 2007.
Robert Gasparini, the Company's President and Chief Scientific Officer, stated, "Although our full results won't be available until next week, we felt that it was important to get our key revenue and operational metrics to the public now. While we are quite pleased with our approximately 115% year-over- year revenue growth in Q4 07 from Q4 06 and our approximately 22% sequential quarterly increase in revenue from Q3 07, we will still be in a net loss position for Q4 07. We have recently received many inquiries from shareholders about downward movements in our stock price. We do not have any information as to why this is happening at this time. There have been no material developments at NeoGenomics that have not already been disclosed. Based on the relatively low trading volumes of our stock over the last 2 or 3 months, we believe that recent declines in our stock price have more to do with downward trends in the overall equity markets than with any change in fundamentals at NeoGenomics. We look forward to answering all investor questions on our March 18th earnings call."
The Company has scheduled a webcast and conference call to discuss their Q4 07 results on March 18th, at 11:00 AM EST. Interested investors should dial (877) 407-0778 (domestic) and (201) 689-8565 (international) at least five minutes prior to the call. A replay of the conference call will be available until 11:59 PM on April 1, 2008 and can be accessed by dialing (877) 660-6853 (domestic) and (201) 612-7415 (international). The playback account number is 286 and the playback conference ID Number/PIN Number is 278576. The web-cast may be accessed under the Investor Relations section of our website at http://www.neogenomics.org or at the website of our Investor Relations firm, Hawk Associates, at http://www.hawkassociates.com/ngnmmore.aspx or at http://www.vcall.com/IC/CEPage.asp?ID=122792. An archive of the web-cast will be available until 11:59 PM EST on June 19, 2008.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.
Interested parties can also access additional investor relations material from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm/ or from Hawk Associates at http://www.hawkassociates.com. An investment profile about NeoGenomics may be found at http://www.hawkassociates.com/ngnmprofile.aspx.
Forward Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.
CONTACT: Steven C. Jones, Director of Investor Relations, NeoGenomics,
Inc., +1-239-325-2001, sjones@neogenomics.org; Frank N. Hawkins or Julie
Marshall, +1-305-451-1888, info@hawkassociates.com, both of Hawk and
Associates, Inc. for NeoGenomics, Inc.
Web site: http://www.neogenomics.org/
http://www.hawkassociates.com/
